Peptilogics Raises $78 Million to Advance Zaloganan Into Pivotal Phase 2/3 Trial for Prosthetic Joint Infections
核心洞察
Peptilogics (搜索) completed an oversubscribed $78 million Series B2 financing round led by Presight Capital (搜索), Thiel Bio (搜索), and Founders Fund (搜索) to advance zaloganan (PLG0206) into a pivotal Phase 2/3 trial for prosthetic joint infections (搜索).
The investigational therapy targets biofilm (搜索) elimination at infection sites, with Phase 1b results showing 93% of patients remaining infection-free at 12 months following zaloganan irrigation during DAIR procedures.
The upcoming randomized, placebo-controlled superiority trial will enroll 240 patients beginning December 2025, addressing a significant unmet need with 45,000 annual PJI cases in the U.S. and no FDA-approved specific therapeutics.
Peptilogics (搜索), a clinical-stage biotechnology company developing surgical therapeutics for medical device infections, has closed an oversubscribed $78 million Series B2 financing round to advance its lead compound zaloganan (PLG0206) into pivotal trials for prosthetic joint infections (搜索) (PJI). The funding round was led by Presight Capital (搜索), Thiel Bio (搜索), and Founders Fund (搜索), with participation from AMR Action Fund (搜索), Narya Capital, and Beyond Ventures.
This latest financing brings Peptilogics (搜索)' total equity funding to approximately $120 million, alongside substantial non-dilutive grant support from CARB-X. The investment will specifically fund a pivotal Phase 2/3 clinical trial targeting one of orthopedic surgery's most challenging complications.
Addressing a Critical Unmet Medical Need
Prosthetic joint infections (搜索) represent a devastating complication affecting an estimated 45,000 patients annually in the United States. These infections can transform successful joint replacements into prolonged medical crises, often requiring multiple surgeries, extended hospitalizations, and costly rehabilitation processes.
Currently, no FDA-approved therapeutic exists specifically for PJI, leaving patients dependent on suboptimal interventions. Standard approaches include DAIR (debridement, antibiotics, and implant retention), which carries a failure rate of approximately 50%, or two-stage revision procedures that still fail in 15-25% of cases despite requiring multiple surgeries and months of disability. Treatment expenses can exceed $390,000 per patient, according to research published in Clinical Orthopedics and Related Research.
"What these investors understood is that hardware-related infections like PJI are different from other common infections," said Jonathan Steckbeck, PhD, CEO of Peptilogics (搜索). "We chose to focus on this huge unmet need because the lack of effective therapeutic options alters the commercial landscape that has made antibiotic development difficult. Developing treatments for these infections allows us to create a new category of surgical therapeutics for patients who currently have to undergo multiple life-changing surgeries to eliminate the infection."
Targeting Biofilm for Enhanced Efficacy
Zaloganan's mechanism of action focuses on eliminating biofilm (搜索)—the bacterial shield that renders most antibiotics ineffective—directly at the infection site. This approach addresses the fundamental challenge in treating hardware-related infections.
"Biofilm (搜索) is the common enemy and the reason why existing standard-of-care surgical interventions fail, even with systemic antibiotics," explained Nick Pachuda, Chief Operating Officer and former orthopedic surgeon at Peptilogics (搜索). "Hardware-related infections are difficult to treat because bacteria on foreign surfaces hide in drug-resistant biofilm that current antibiotics cannot eliminate. Zaloganan quickly penetrates the biofilm locally and kills the hiding bacteria."
In Peptilogics (搜索)' Phase 1b study, zaloganan irrigation administered during DAIR procedures demonstrated promising efficacy, with 13 of 14 patients (93%) remaining infection-free at 12 months. These encouraging results supported the company's advancement into pivotal trials.
Pivotal Trial Design and Regulatory Support
The upcoming randomized, placebo-controlled Phase 2/3 superiority trial will enroll 240 patients beginning in December 2025. The primary endpoint will measure reductions in clinical failure rates, with secondary analyses focusing on health economics measures including hospital stays, readmissions, and surgical burden to quantify potential cost savings for healthcare systems.
Peptilogics (搜索) has secured multiple U.S. FDA regulatory designations for zaloganan that support expedited development:
- Qualified Infectious Disease Product (QIDP) designation, providing 5 additional years of market exclusivity upon approval
- Orphan Drug Designation for PJI treatment
- Fast Track Designation to facilitate development and expedite FDA review
Growing Market Opportunity
The clinical challenge is expanding alongside increasing demand for joint replacement procedures. Projections indicate that by 2030, the U.S. will see 3.48 million knee and 572,000 hip replacement procedures annually, each carrying PJI risk that current medicine cannot fully manage.
"Periprosthetic joint infections are a striking example of how antimicrobial resistance is rapidly undermining modern medicine," said Henry Skinner, PhD, CEO of AMR Action Fund (搜索). "The financial costs, diminished quality of life, and mortality associated with such infections are frankly unacceptable, and we are pleased to support the Peptilogics (搜索) team as they advance zaloganan through the clinic and toward patients in need."
The investor syndicate includes firms that have previously supported leading biopharma innovators such as AbCellera, Compass Pathways, and Kriya Therapeutics, reflecting confidence in both Peptilogics (搜索)' scientific approach and commercial potential. For healthcare systems, effective PJI treatment could deliver significant value through reduced hospital stays, fewer repeat surgeries, and improved care coordination.